



D-2937

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In application of:
YUAN et al.

Serial No. 09/848,159

Filed: May 3, 2001

For: METHOD FOR TREATING
HYPERLIPIDEMIA

Examiner: Hui, S.

Group Art Unit: 1617

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on or before

March 6, 2003

Art. McGhee

Title Aspirin

Date 3/6/03

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed pursuant to 37 CFR 1.97(c) and is accompanied by a certification as specified in 37 CFR 1.97(e).

CERTIFICATION UNDER 37 CFR 1.97(e)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication (the International Search Report) from a foreign patent office (The

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900
S/11/B

European Patent Office) acting as the International Search Authority in a counterpart foreign (PCT) patent application no more than three months prior to the filing of this Supplemental Information Disclosure Statement (a copy of the International Search Report is enclosed).

Respectfully submitted,



Frank G. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

FJUxa/ac